Reversal of Scopolamine-Related Deficits in Cognitive Functions by ZT-1, A Huperzine-A Derivative | Debio 9902 - ZT-1 | /

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Reversal of Scopolamine-Related Deficits in Cognitive Functions by ZT-1, A Huperzine-A Derivative

9th International Geneva Springfield Symposium on Advanced Alzheimer Therapy
April 19-22, 2006

A. Zangara, C. Edgar, K. Wesnes, P. Scalfaro*, H. Porchet*

*Debiopharm
poster_in_PDF